Efficacy of motesanib diphosphate in non-small-cell lung cancer

Erika Rijavec, Carlo Genova, Giulia Barletta, Federica Biello, Maria Giovanna Dal Bello, Simona Coco, Anna Truini, Irene Vanni, Angela Alama, Francesco Boccardo, Francesco Grossi

Research output: Contribution to journalArticlepeer-review


Introduction: Angiogenesis plays a crucial role in the proliferation and in the metastatic spread of tumour cells. Several agents with anti-angiogenic activity have been tested in advanced non-small-cell lung cancer (NSCLC) patients. Motesanib (AMG 706) is a promising anti-angiogenic multi-targeted tyrosine kinase inhibitor (TKI), which has been investigated as a monotherapy or in combination with chemotherapy, in several types of cancer.Areas covered: We have reviewed the literature, and we have presented the results of clinical trials that have investigated the administration of motesanib in advanced NSCLC patients.Expert opinion: Encouraging results have been described with the administration of motesanib as first-line treatment in combination with carboplatin and paclitaxel in Asian patients with non-squamous advanced NSCLC. Further studies are needed in order to identify the predictive biomarkers of response and to select patients who may benefit from this anti-angiogenic treatment.

Original languageEnglish
Pages (from-to)1771-1780
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Issue number12
Publication statusPublished - 2014


  • Angiogenesis
  • Motesanib
  • Multi-targeted tyrosine kinase inhibitors
  • Non-small-cell lung cancer

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Fingerprint Dive into the research topics of 'Efficacy of motesanib diphosphate in non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this